<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198393</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0301</org_study_id>
    <nct_id>NCT00198393</nct_id>
  </id_info>
  <brief_title>Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV</brief_title>
  <official_title>Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting a deterioration of the general state (performance status [PS] 2-3),
      constitute a population which needs an adapted treatment. An analysis was made of the
      evolution of PS 2 patients included in the Eastern Cooperative Oncology Group (ECOG) 1594
      trial which evaluated associations of new cytotoxic agents (gemcitabine, paclitaxel,
      docetaxel) with cisplatin. During this trial, the inclusion of these patients stopped due to
      the occurrence of toxicities more frequent than in the other populations (PS 0-1). At the end
      of this study, with the analysis of total toxicity, this one was not higher than that noted
      in the groups of PS 0 and 1 patients. In the population of PS 2 patients, 5 deaths had been
      noted, but the analysis showed that only 2 were due to the treatment. It was noted that the
      lower survival compared to the others was related to the disease and not to the treatment.
      These patients are often symptomatic and need palliative treatment. The benefit of
      chemotherapy should not be denied. They should profit from a monochemotherapy with the new
      cytotoxic agents, without associated platinum salt.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm A Iressa 250 mg daily PROG/TOX --&gt; Taxotere 75 mg/m² d1 (d1=d22)

      Arm B Gemzar 1250 mg/m² d1 &amp; d8 (d1=d22) PROG/TOX --&gt; Iressa 250 mg daily

      Arm C Taxotere 75 mg/m² d1 (d1=d22) PROG/TOX --&gt; Iressa 250 mg daily
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250 mg/day, until progression</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1250 mg/m² D1 and D8 (D1=D28, until progression)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m² D1 (D1=D22, until progression)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIB/IV NSCLC

          -  patients with performance status 2 or 3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Morere, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFCT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Moro-Sibilot, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Avicenne - Oncologie</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - pneumologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>Official website</description>
  </link>
  <reference>
    <citation>Moro-Sibilot D, Pluquet E, Zalcman G, Bréchot JM, Souquet PJ, Debieuvre D, Morin F, Morère JF. [What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?]. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S120-4. Review. French.</citation>
    <PMID>18235404</PMID>
  </reference>
  <results_reference>
    <citation>Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer. 2010 Dec;70(3):301-7. doi: 10.1016/j.lungcan.2010.03.003. Epub 2010 Apr 18.</citation>
    <PMID>20400201</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 28, 2010</last_update_submitted>
  <last_update_submitted_qc>April 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pr Jean-François Morère</name_title>
    <organization>Intergroupe Francophone de Cancérologie Thoracique</organization>
  </responsible_party>
  <keyword>stage IIIB/IV NSCLC</keyword>
  <keyword>patients with performance status 2 or 3.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

